Trials / Conditions / Indolent B-Cell Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma

11 registered clinical trials studyying Indolent B-Cell Non-Hodgkin Lymphoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265	Verismo Therapeutics	Phase 1
Recruiting	Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma NCT06386315	Mayo Clinic	Phase 2
Recruiting	Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma NCT06461182	Koo Foundation Sun Yat-Sen Cancer Center	Phase 2
Unknown	Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis Wit NCT05803395	Gruppo Italiano Malattie EMatologiche dell'Adulto	—
Active Not Recruiting	Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic NCT05665062	Synthekine	Phase 1
Active Not Recruiting	Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma NCT05621096	University of Nebraska	Phase 1
Completed	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-C NCT05169658	University of Washington	Phase 2
Active Not Recruiting	ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600	Joseph Tuscano	Phase 1
Terminated	Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases NCT03498612	University of Washington	Phase 2
Recruiting	A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cel NCT03571568	BioInvent International AB	Phase 1 / Phase 2